Benzylideneacetone derivative and use thereof
AssigneesKorpharm Co., Ltd., Gyeonggido Business & Science Accelerator, Korea University Research and Business Foundation
InventorsGil Hong Park, Jin Mo Ku, Jung Hun Lee, Da Woon Song, Serk In Park, Han Kyeom Kim, Soon Hyuck Lee, Hong Kyu Kim, Pativada Triveni, Myung Hwan Kim
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel benzylideneacetone derivatives or uses thereof, more specifically, the present invention relates to a pharmaceutical composition for preventing or treating, or food composition for ameliorating a cancer or a bone disease comprising a compound defined by Formula 1 or pharmaceutically acceptable salt thereof as an active ingredient.
Claims2
A method for treating a bone cancer in a subject, the method comprising administering to the subject in need thereof an effective amount of a composition comprising a compound defined by Formula 1 below or the pharmaceutically acceptable salt thereof as an active ingredient:
- wherein, R1 and R2 are different from each other,
- R1 and R2 are each independently selected from the group consisting of —H, —OH, —SH, C1-4 straight or branched alkyl, C1-4 straight or branched alkoxy, halogen, allyloxy, benzyloxy, aryloxy having one or more selected from the group consisting of hetero atoms and substituents, and heterocycloalkyl of 3 to 7 atoms having one or more hetero atoms, wherein the hetero atoms consist of
- 0, N and S;
- R3 is one selected from the group consisting of Ci-4 straight or branched alkyl, —NH2, —NHR4, —N(R4)2, and —OH;
- and
- R4 is C1-4 straight or branched alkyl,
- wherein the compound defined by Formula 1 is selected from the group consisting of the following compounds;
- (1) (E)-4-(4-hydroxy-3-methoxyphenyl)-3-buten-2-one;
- (2) (E)-4-(3-hydroxy-4-methoxyphenyl)-3-buten-2-one;
- and
- (3) (E)-4-(3-fluoro-4-hydroxyphenyl)-3-buten-2-one.
A method for treating osteoporosis in a subject, the method comprising administering to the subject in need thereof an effective amount of a composition comprising a compound defined by Formula 1 below or the pharmaceutically acceptable salt thereof as an active ingredient:
- wherein, R1 and R2 are different from each other,
- R1 and R2 are each independently selected from the group consisting of —H, —OH, —SH, C1-4 straight or branched alkyl, C1-4 straight or branched alkoxy, halogen, allyloxy, benzyloxy, aryloxy having one or more selected from the group consisting of hetero atoms and substituents, and heterocycloalkyl of 3 to 7 atoms having one or more hetero atoms, wherein the hetero atoms consist of
- 0, N and S;
- R3 is one selected from the group consisting of Ci-4 straight or branched alkyl, —NH2, —NHR4, —N(R4)2, and —OH;
- and
- R4 is C1-4 straight or branched alkyl,
- wherein the compound defined by Formula 1 is selected from the group consisting of the following compounds;
- (1) (E)-4-(3-hydroxy-4-methoxyphenyl)-3-buten-2-one;
- and
- (2) (E)-4-(3-fluoro-4-hydroxyphenyl)-3-buten-2-one.
Dependencies are inferred from the claim text.